KDR and ovarian carcinoma: The completely humanized SDC-1 recombinant antibody OC-46F2 reduces SDC-1/VEGFR-2 activity in tumor microenvironments, consequently blocking vascular maturation and tumor growth in the setting of malignant melanoma and experimental models of ovarian cancer (Orecchia et al., 2013).